Image by go elsewhere… via Flickr
Lilly, on Wednesday, announced that it would not seek regulatory approval for its osteoporosis treatment arzoxifene, because the drug failed to meet certain end points in Phase III clinical trials.
The good news is that the drug was successful in meeting the primary end point of the trial, dubbed “GENERATIONS.†[...]
Lilly Osteoporosis Drug Canned in Phase III Trials